Beam Therapeutics/$BEAM

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Beam Therapeutics

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Ticker

$BEAM
Primary listing

Industry

Biotechnology

Employees

393

ISIN

US07373V1052
Website

BEAM Metrics

BasicAdvanced
$2B
-
-$4.62
2.35
-

What the Analysts think about BEAM

Analyst ratings (Buy, Hold, Sell) for Beam Therapeutics stock.

Bulls say / Bears say

Beam Therapeutics reported positive initial data from its Phase 1/2 trial of BEAM-302 for Alpha-1 Antitrypsin Deficiency, showing durable, dose-dependent increases in total and functional AAT, and reductions in mutant Z-AAT levels. (investing.com)
The company's BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease demonstrated that all treated patients achieved Hemoglobin F induction of over 60% and Hemoglobin S reduction to below 40%, with no vaso-occlusive crises post-treatment. (gurufocus.com)
Beam Therapeutics received Orphan Drug Designation from the U.S. FDA for both BEAM-101 and BEAM-302, potentially facilitating expedited development and regulatory processes. (globenewswire.com)
In Q1 2025, Beam Therapeutics reported a net loss of over $109 million, deepening from the previous year's loss, and missed analyst revenue expectations, leading to a significant stock price decline. (nasdaq.com)
The company faces high competition in the sickle cell disease and Alpha-1 Antitrypsin Deficiency sectors, with analysts expressing concerns about its ability to differentiate its therapies in a crowded market. (investing.com)
Insider selling activity, including significant share sales by the CEO and President, may raise concerns about internal confidence in the company's future performance. (defenseworld.net)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

BEAM Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BEAM Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BEAM

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs